Literature DB >> 8912541

p53 protein is absent from the serum of patients with lung cancer.

M A Levesque1, M D'Costa, E P Diamandis.   

Abstract

p53 protein, which accumulates intracellularly in over half of all human tumours, has also been reported to be present in the sera of patients with various malignancies, including lung cancer. Using a quantitative immunoassay, we measured p53 protein concentrations in 216 sera from 114 lung cancer patients of whom 75 provided matched lung tumour tissues, which were also assayed for p53 protein. p53 protein levels above the detection limit of 0.04 ng ml-1 were detected in only two sera from lung cancer patients (0.14 ng ml-1 and 0.27 ng ml-1), but not in any of 13 sera from non-malignant lung disease patients or in 100 sera from normal non-diseased individuals. The presence of these apparent traces of serum p53 protein concentrations could not be related either to the p53 protein expression status of the primary lung tumours or to the tumour stage, grade or histological type. By pretreating these two sera with anti-p53 antibody linked to solid phase, and by the addition of mouse serum to neutralise possible heterophilic antibodies, the signals arising from these sera were shown to be non-specific and possibly caused by heterophilic antibodies. We conclude that our data do not support previous reports of p53 protein in the sera of lung cancer patients. Since immunoassays are subject to numerous sources of interference in serum, including heterophilic antibodies, we suggest that the results of p53 protein analysis of serum specimens should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912541      PMCID: PMC2074762          DOI: 10.1038/bjc.1996.561

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  49 in total

1.  Detection of serum p53 protein in lung cancer patients.

Authors:  J C Luo; R Zehab; S Anttila; M Ridanpaa; K Husgafvel-Pursiainen; H Vainio; W Carney; I De Vivo; C Milling; P W Brandt-Rauf
Journal:  J Occup Med       Date:  1994-02

2.  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.

Authors:  K Angelopoulou; E P Diamandis; D J Sutherland; J A Kellen; P S Bunting
Journal:  Int J Cancer       Date:  1994-08-15       Impact factor: 7.396

3.  Accumulation of nuclear p53 and tumor progression in bladder cancer.

Authors:  D Esrig; D Elmajian; S Groshen; J A Freeman; J P Stein; S C Chen; P W Nichols; D G Skinner; P A Jones; R J Cote
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

4.  Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history.

Authors:  H Dosaka-Akita; M Shindoh; M Fujino; I Kinoshita; K Akie; M Katoh; Y Kawakami
Journal:  Am J Clin Pathol       Date:  1994-11       Impact factor: 2.493

5.  p53 genetic abnormalities and myc activation in human lung carcinoma.

Authors:  S Gazzeri; E Brambilla; C Caron de Fromentel; V Gouyer; D Moro; P Perron; F Berger; C Brambilla
Journal:  Int J Cancer       Date:  1994-07-01       Impact factor: 7.396

6.  p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.

Authors:  H Pappot; D Francis; N Brünner; J Grondahl-Hansen; K Osterlind
Journal:  Clin Cancer Res       Date:  1996-01       Impact factor: 12.531

7.  Detection of oncogene mutations in sputum precedes diagnosis of lung cancer.

Authors:  L Mao; R H Hruban; J O Boyle; M Tockman; D Sidransky
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

8.  Detection of C-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions.

Authors:  C Greco; G M Gandolfo; F Mattei; A Gradilone; S Alvino; L I Pastore; V Casale; P Casole; A Grassi; A M Cianciulli
Journal:  Anticancer Res       Date:  1994 May-Jun       Impact factor: 2.480

9.  Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein.

Authors:  B Schlichtholz; J Trédaniel; R Lubin; G Zalcman; A Hirsch; T Soussi
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

10.  p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas.

Authors:  C Walker; L J Robertson; M W Myskow; N Pendleton; G R Dixon
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more
  2 in total

1.  Humoral immune response to p53 in malignant glioma.

Authors:  M Weller; A Bornemann; M Ständer; M Schabet; J Dichgans; R Meyermann
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

2.  p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.

Authors:  J Schneider; P Presek; A Braun; P Bauer; N Konietzko; B Wiesner; H J Woitowitz
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.